Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Insulin Degludec/Liraglutide.

Baker DE.

Hosp Pharm. 2017 May;52(5):374-380. doi: 10.1177/0018578717715383. Epub 2017 May 1. Review.

PMID:
28804155
2.

[Anti-IL-6 : new therapeutic trends].

Candil M, Zufferey P.

Rev Med Suisse. 2017 Jan 11;13(544-545):105-109. Review. French.

PMID:
28703549
3.

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.

Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG.

Drug Des Devel Ther. 2017 May 24;11:1593-1603. doi: 10.2147/DDDT.S100302. eCollection 2017. Review.

4.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

PMID:
28264816
5.

From mechanism to therapies in systemic lupus erythematosus.

Paley MA, Strand V, Kim AH.

Curr Opin Rheumatol. 2017 Mar;29(2):178-186. doi: 10.1097/BOR.0000000000000369. Review.

PMID:
28118202
6.

Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders.

Fasching P, Stradner M, Graninger W, Dejaco C, Fessler J.

Molecules. 2017 Jan 14;22(1). pii: E134. doi: 10.3390/molecules22010134. Review.

7.

Sirukumab: A Potential Treatment for Mood Disorders?

Zhou AJ, Lee Y, Salvadore G, Hsu B, Fonseka TM, Kennedy SH, McIntyre RS.

Adv Ther. 2017 Jan;34(1):78-90. doi: 10.1007/s12325-016-0455-x. Epub 2016 Dec 2. Review.

8.

Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date.

Lazzerini PE, Capecchi PL, Guidelli GM, Selvi E, Acampa M, Laghi-Pasini F.

Drug Des Devel Ther. 2016 Sep 26;10:3083-3098. eCollection 2016. Review.

9.

Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis.

Furie R, Toder K, Zapantis E.

Semin Nephrol. 2015 Sep;35(5):509-20. doi: 10.1016/j.semnephrol.2015.08.012. Review.

PMID:
26573553
10.

Targeting interleukin-6 for noninfectious uveitis.

Lin P.

Clin Ophthalmol. 2015 Sep 11;9:1697-702. doi: 10.2147/OPTH.S68595. eCollection 2015. Review.

11.

IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.

Kim GW, Lee NR, Pi RH, Lim YS, Lee YM, Lee JM, Jeong HS, Chung SH.

Arch Pharm Res. 2015;38(5):575-84. doi: 10.1007/s12272-015-0569-8. Epub 2015 Feb 4. Review.

PMID:
25648633
12.

Antibodies to watch in 2015.

Reichert JM.

MAbs. 2015;7(1):1-8. doi: 10.4161/19420862.2015.988944. Review.

13.

Sirukumab : a novel therapy for lupus nephritis?

Thanarajasingam U, Niewold TB.

Expert Opin Investig Drugs. 2014 Oct;23(10):1449-55. doi: 10.1517/13543784.2014.950837. Epub 2014 Sep 5. Review.

PMID:
25189410

Supplemental Content

Loading ...
Support Center